| TRAE | 1-year probability | Source |
|---|---|---|
| Oral corticosteroids (prednisolone) | ||
| Cataracts | 2.42% | Eigan 1995 (calculated from 1mg 4-year follow-up and 2mg 3-year follow-up) |
| Reduced BMD | 2.42% | Assumed to equal cataracts based on similar risks (very rare) reported in the eMC |
| Diabetes | 1.48% | Eigan 1995 (calculated from 1mg 4-year follow-up and 2mg 3-year follow-up) |
| Macrolides (azithromycin) | ||
| Hearing impairment | 1.10% | Saimen 2003 & Saimen 2010 |
| NSAIDs (ibuprofen) | ||
| Abdominal pain | 4.33% | Gabrial 1991 |
| Abdominal bleed | 0.70% | Lands 2007 |
| Renal impairment | 0.70% | Assumed to equal abdominal bleed based on similar risks (very rare) reported in the eMC |
BMD, bone mineral density; eMC, electronic Medicines Compendium; NSAID, nonsteroidal antiinflammatory drugs; TRAE, treatment related adverse event
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.